Arylamine N-acetyltransferase (NAT2) gene mutations in children with allergic diseases

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 6, 1997, Pages 635-642

  Zielińska, Elzbieta ^a   Niewiarowski, Wojciech ^b   Bodalski, Jerzy ^b   Stańczyk, Anna ^b   Bolanowski, Wojciech ^b   Rȩbowski, Grzegorz ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; DNA; IMMUNOGLOBULIN E; NUCLEOTIDE;

ACETYLATION; ACETYLATOR PHENOTYPE; ADOLESCENT; ALLELE; ARTICLE; ATOPY; CHILD; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; FEMALE; FOOD ALLERGY; GENE; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLLEN ALLERGY; POLYMERASE CHAIN REACTION; PRICK TEST; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ARYLAMINE N-ACETYLTRANSFERASE; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC MARKERS; GENOTYPE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; INFANT; MALE; POINT MUTATION; POLAND;

EID: 0031409368     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90083-7     Document Type: Article

References (35)

1. Weber WW, Hein DW. N-Acetylation pharmacogenetics. Pharmacol Rev 1985;37:25-79.
2. Van der Berg GA, Muskiet FAJ, Kingma AW, van der Slik W, Halie MR. Simultaneous gas-chromatographic determination of free and acetyl-conjugated poliamines in urine. Clin Chem 1986;32:1930-6.
3. Tabor H, Mehler AH, Stadtman ER. The enzymatic acetylation of amines. J Biol Chem 1953;204:127-38.
4. Aisien SO, Walter RD. Biogenic amine acetylation: an additional function of the N-acetyltransferase from Fasciola hepatica. Biochem J 1993;291:733-7.
5. Maslinski C, Fogel A. Catabolism of histamine. In: Uväns B, editor. Handbook of experimental pharmacology: histamine and histamine antagonists. Berlin: Springer-Verlag; 1991, 1997. p. 165-89.
6. Endo Y. Elevation of histamine levels in rat and mouse tissue by deacetylation of administered N-acetylhistamine. Eur J Pharmacol 1979;60:299-305.
7. 2 receptor and proton pump inhibitors on some functions of the oxidative and conjugative drug metabolism. Pharmazie 1996;51: 493-7.
8. 2 receptor antagonists on the rat liver cytosolic acetyl CoA:arylamine N-acetyltransferase activity. Drug Metab Dispos 1992; 20:74-8.
9. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993;14:1689-92.
10. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotype activity. Am J Hum Genet 1995;57:581-92.
11. Deguchi T. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem 1992;267:18140-7.
12. Ferguson RJ, Doll MA, Rustan TD, Gray K, Hein DW. Cloning, expression, and functional characterisation of two mutant (NAT2 191 and NAT2 341/803) and wild-type human polymorphic N-acetyltransferase (NAT2) alleles. Drug Metab Dispos 1994;22:371-6.
13. Hein DW, Ferguson RJ, Doll MA, Rustan TD, Gray K. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum Mol Genet 1994;3:729-34.
14. Hickman D, Sim E. N-Acetyltransferase polymorphism: comparison of phenotype and genotype in humans. Biochem Pharmacol 1991;42:1007-14.
15. Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci USA 1991;88: 6333-7.
16. Braz Vieira da Silva Pontes Z, Vincent-Viry M, Gueguen MM, Galteau MM, Siest G. Acetylation phenotypes and biological variation in a French population. Eur J Clin Chem Clin Biochem 1993;31:59-68.
17. Clark DWJ. Genetically determined variability in acetylation and oxidation: therapeutic implications. Drugs 1985;29:342-75.
18. Carr A, Gross AS, Hoskins JM, Penny R, Cooper DA. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS 1994;8:333-7.
19. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991;49:13-7.
20. Risch A, Wallace DMA, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 1995;4:231-6.
21. Patkowski J, Malolepszy J, Milejski P, Orzechowska-Juzwenko K, Nittner-Marszalska M. Acetylation phenotype in the atopic allergy. Pol Tyg Lek 1987;42: 870-3.
22. Rolfs A, Schuller I, Fincken U, Weber-Rolfs I. PCR clinical diagnostics and research. Berlin: Springer-Verlag; 1992. p. 79-89.
23. Vatsis KP, Weber WW, Bell DA, Dupert JM, Evans DAP, Grant DM, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1-17.
24. Mrozikiewicz PM, Cascorbi I, Brockmöller J, Roots I. Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Clin Pharmacol Ther 1996;59:376-82.
25. Vesell ES. The model drug approach in clinical pharmacology. Clin Pharmacol Ther 1991;50:239-48.
26. Zielińska E, Niewiarowski W, Bodalski J, Rebowski G, Skretkowicz J, Polakowski P, et al. Relation between genotype for human arylamine N-acetyltransferase (NAT2) and phenotype acetylation in the children under 2 years old. Therapie 1995; 84(suppl):84.
27. Agúndez JAG, Martinez C, Olivera M, Ledesma MC, Ladero JM, Benitez J. Molecular analysis of the arylamine N-acetyltransferase polymorphism in a Spanish population. Clin Pharmacol Ther 1994;56: 202-9.
28. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens. Proc Natl Acad Sci USA 1991; 88:5237-41.
29. Hickman D, Risch A, Camilleri JP, Sim E. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics 1992;2:217-26.
30. Zielińska E, Niewiarowski W, Bodalski J, Rȩbowski G, Matusiak I. Molecular genotyping of the arylamine N-acetyltransferase polymorphism in children. Med Sci Monit [in press].
31. Grant DM. Molecular genetics of the N-acetyltransferases. Pharmacogenetics 1993;3:45-50.
32. Rodriguez JW, Kirlin WG, Ferguson RJ, Doll MA, Gray K, Rustan TD, et al. Human acetylator genotype: relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol. Arch Toxicol 1993;67:445-52.
33. Lin HJ, Han CY, Lin BK, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am J Hum Genet 1993;52:827-34.
34. Crimi N, Polosa R, Magri S, Prosperini G, Paolino G, Mastruzzo C. Inhalated lysine acetylsalicylate (L-ASA) attenuates histamine-induced bronchoconstraction in asthma. Allergy 1996;51:157-63.
35. Dyduch A, Geisler G, Pieniazek W, Schneiberg B, Iwachow T, Siekulski J. Physiological and pathophysiological role of histamine in the gastrointestinal tract. Pediatr Pol 1996;71:391-5.